Product Code: PM3053
The global Ewing sarcoma therapeutics market size is expected to reach USD 424.42 million by 2032, according to a new study by Polaris Market Research. The report "Ewing Syndrome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Infoposide, Dactinomycin); By Treatment; By Application; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Global growth in illness knowledge and incidence, as well as efforts made by government organizations, are driving the Ewing sarcoma market. Ewing sarcoma affects 2.9 children per 100,000 each year, according to the National Organization for Rare Diseases. Every year, around 200-250 children and adolescents in the United States are diagnosed with Ewing family tumors, with two-thirds expected to survive a long period.
Other factors driving the Ewing sarcoma therapy market include increased R&D and technology breakthroughs in diagnostics supporting market expansion. In May 2021, CancerVAX, Inc. launched research programmed to create the company's first Immunotherapy cancer treatment, which would mostly target Ewing sarcoma. Wings for Ewing Sarcoma, a non-profit 501(c)(3) group, is also working to discover a cure for the illness. They seek to empower children and young adults who are presently fighting until a treatment is discovered.
Drugs that target the IGF-1R, a protein present on the certain type of cancer cells that stimulates them to proliferate, are in clinical studies. Early research suggests that medications like these, such as ganitumab, can reduce some Ewing tumors while slowing the growth of others. In most situations, this improvement has only been transitory. These treatments may perform best when combination with additional medications, which are currently being investigated.
Ewing sarcoma, the second most frequent kind of bone tumor in children, is caused by an aberrant protein known as EWS/FLI. In January 2018, according to researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a new class of cancer medications known as CDK inhibitors may be able to disarm EWS/FLI.
Ewing Syndrome Therapeutics Market Report Highlights:
Chemotherapy treatment accelerated the overall growth of the market as chemotherapy employs a stronger treatment pathway for treatment of ewing sarcoma.
Bone tumor accounted for high CAGR as it has most frequent types of ewing tumors due to different types of cells forming tumors as compared to osteosarcoma cells.
North America has the biggest market share due to the rising frequency of Ewing sarcoma and the ease with which medicines are available.
The global players Abbott, AbbVie, Amgen Inc, AstraZeneca, Bausch, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, AbbVie Inc, GlaxoSmithKline, Johnson & Johnson, Novartis, and Sanofi.
Polaris Market Research has segmented the Ewing sarcoma therapeutics market report based on drug class, treatment, application, and region:
Ewing Sarcoma Therapeutics, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)
Vincristine,
Cyclophosphamide
Doxorubicin
Etoposide
Infoposide
Dactinomycin
Ewing Sarcoma Therapeutics, Treatment Outlook (Revenue - USD Million, 2019 - 2032)
Chemotherapy
Radiation
Surgery
Ewing Sarcoma Therapeutics, Application Outlook (Revenue - USD Million, 2019 - 2032)
Bone Tumor
Soft Tissue Tumor
Askin Tumor
Ewing Sarcoma Therapeutics, Regional Outlook (Revenue - USD Million, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Ewing Sarcoma Therapeutics Market Insights
- 4.1. Ewing Sarcoma Therapeutics Market - Application Snapshot
- 4.2. Ewing Sarcoma Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increased frequency of bone-related illnesses
- 4.2.1.2. Substantial investment by private businesses
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost for treatment
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Ewing Sarcoma Therapeutics Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Ewing Sarcoma Therapeutics Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 5.3. Vincristine
- 5.3.1. Global Ewing Sarcoma Therapeutics Market, by Vincristine, by Region, 2019-2032 (USD Million)
- 5.4. Cyclophosphamide
- 5.4.1. Global Ewing Sarcoma Therapeutics Market, by Cyclophosphamide, by Region, 2019-2032 (USD Million)
- 5.5. Doxorubicin
- 5.5.1. Global Ewing Sarcoma Therapeutics Market, by Doxorubicin, by Region, 2019-2032 (USD Million)
- 5.6. Etoposide
- 5.6.1. Global Ewing Sarcoma Therapeutics Market, by Etoposide, by Region, 2019-2032 (USD Million)
- 5.7. Infoposide
- 5.7.1. Global Ewing Sarcoma Therapeutics Market, by Infoposide, by Region, 2019-2032 (USD Million)
- 5.8. Dactinomycin
- 5.8.1. Global Ewing Sarcoma Therapeutics Market, by Dactinomycin, by Region, 2019-2032 (USD Million)
6. Global Ewing Sarcoma Therapeutics Market, by Treatment
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 6.3. Chemotherapy
- 6.3.1. Global Ewing Sarcoma Therapeutics Market, by Chemotherapy, by Region, 2019-2032 (USD Million)
- 6.4. Radiation
- 6.4.1. Global Ewing Sarcoma Therapeutics Market, by Radiation, by Region, 2019-2032 (USD Million)
- 6.5. Surgery
- 6.5.1. Global Ewing Sarcoma Therapeutics Market, by Surgery, by Region, 2019-2032 (USD Million)
7. Global Ewing Sarcoma Therapeutics Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 7.3. Bone Tumour
- 7.3.1. Global Ewing Sarcoma Therapeutics Market, by Bone Tumour, By Region, 2019-2032 (USD Million)
- 7.4. Soft Tissue Tumour
- 7.4.1. Global Ewing Sarcoma Therapeutics Market, by Soft Tissue Tumour, By Region, 2019-2032 (USD Million)
- 7.5. Askin Tumour
- 7.5.1. Global Ewing Sarcoma Therapeutics Market, by Askin Tumour, By Region, 2019-2032 (USD Million)
8. Global Ewing Sarcoma Therapeutics Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Ewing Sarcoma Therapeutics Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Ewing Sarcoma Therapeutics Market - North America
- 8.3.1. North America: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.2. North America: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.3.3. North America: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.3.4. Ewing Sarcoma Therapeutics Market - U.S.
- 8.3.4.1. U.S.: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.3.5. Ewing Sarcoma Therapeutics Market - Canada
- 8.3.5.1. Canada: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4. Ewing Sarcoma Therapeutics Market - Europe
- 8.4.1. Europe: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.2. Europe.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.3. Europe: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4.4. Ewing Sarcoma Therapeutics Market - UK
- 8.4.4.1. UK: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.4.3. UK: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4.5. Ewing Sarcoma Therapeutics Market - France
- 8.4.5.1. France: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.5.2. France.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.5.3. France: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4.6. Ewing Sarcoma Therapeutics Market - Germany
- 8.4.6.1. Germany: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4.7. Ewing Sarcoma Therapeutics Market - Italy
- 8.4.7.1. Italy: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4.8. Ewing Sarcoma Therapeutics Market - Spain
- 8.4.8.1. Spain: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4.9. Ewing Sarcoma Therapeutics Market - Netherlands
- 8.4.9.1. Netherlands: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.4.10. Ewing Sarcoma Therapeutics Market - Russia
- 8.4.10.1. Russia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.5. Ewing Sarcoma Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.5.4. Ewing Sarcoma Therapeutics Market - China
- 8.5.4.1. China: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.4.2. China.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.5.4.3. China: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.5.5. Ewing Sarcoma Therapeutics Market - India
- 8.5.5.1. India: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.5.2. India.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.5.5.3. India: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.5.6. Ewing Sarcoma Therapeutics Market - Malaysia
- 8.5.6.1. Malaysia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.5.7. Ewing Sarcoma Therapeutics Market - Japan
- 8.5.7.1. Japan: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.5.8. Ewing Sarcoma Therapeutics Market - Indonesia
- 8.5.8.1. Indonesia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.5.9. Ewing Sarcoma Therapeutics Market - South Korea
- 8.5.9.1. South Korea: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.6. Ewing Sarcoma Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.6.4. Ewing Sarcoma Therapeutics Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.6.5. Ewing Sarcoma Therapeutics Market - UAE
- 8.6.5.1. UAE: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.6.6. Ewing Sarcoma Therapeutics Market - Israel
- 8.6.6.1. Israel: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.6.7. Ewing Sarcoma Therapeutics Market - South Africa
- 8.6.7.1. South Africa: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.7. Ewing Sarcoma Therapeutics Market - Latin America
- 8.7.1. Latin America: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.7.3. Latin America: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.7.4. Ewing Sarcoma Therapeutics Market - Mexico
- 8.7.4.1. Mexico: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.7.5. Ewing Sarcoma Therapeutics Market - Brazil
- 8.7.5.1. Brazil: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
- 8.7.6. Ewing Sarcoma Therapeutics Market - Argentina
- 8.7.6.1. Argentina: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott
- 10.1.1. Company Overview
- 10.1.2. Financial PerTreatmentance
- 10.1.3. Treatment Benchmarking
- 10.1.4. Recent Development
- 10.2. AbbVie
- 10.2.1. Company Overview
- 10.2.2. Financial PerTreatmentance
- 10.2.3. Treatment Benchmarking
- 10.2.4. Recent Development
- 10.3. Amgen
- 10.3.1. Company Overview
- 10.3.2. Financial PerTreatmentance
- 10.3.3. Treatment Benchmarking
- 10.3.4. Recent Development
- 10.4. AstraZeneca
- 10.4.1. Company Overview
- 10.4.2. Financial PerTreatmentance
- 10.4.3. Treatment Benchmarking
- 10.4.4. Recent Development
- 10.5. Bausch
- 10.5.1. Company Overview
- 10.5.2. Financial PerTreatmentance
- 10.5.3. Treatment Benchmarking
- 10.5.4. Recent Development
- 10.6. Bayer
- 10.6.1. Company Overview
- 10.6.2. Financial PerTreatmentance
- 10.6.3. Treatment Benchmarking
- 10.6.4. Recent Development
- 10.7. Bristol Squibb
- 10.7.1. Company Overview
- 10.7.2. Financial PerTreatmentance
- 10.7.3. Treatment Benchmarking
- 10.7.4. Recent Development
- 10.8. Eli Lilly
- 10.8.1. Company Overview
- 10.8.2. Financial PerTreatmentance
- 10.8.3. Treatment Benchmarking
- 10.8.4. Recent Development
- 10.9. Merck
- 10.9.1. Company Overview
- 10.9.2. Financial PerTreatmentance
- 10.9.3. Treatment Benchmarking
- 10.9.4. Recent Development
- 10.10. AbbVie Inc
- 10.10.1. Company Overview
- 10.10.2. Financial PerTreatmentance
- 10.10.3. Treatment Benchmarking
- 10.10.4. Recent Development
- 10.11. GlaxoSmithKline
- 10.11.1. Company Overview
- 10.11.2. Financial PerTreatmentance
- 10.11.3. Treatment Benchmarking
- 10.11.4. Recent Development
- 10.12. Johnson & Johnson
- 10.12.1. Company Overview
- 10.12.2. Financial PerTreatmentance
- 10.12.3. Treatment Benchmarking
- 10.12.4. Recent Development
- 10.13. Novartis
- 10.13.1. Company Overview
- 10.13.2. Financial PerTreatmentance
- 10.13.3. Treatment Benchmarking
- 10.13.4. Recent Development
- 10.14. Sanofi
- 10.14.1. Company Overview
- 10.14.2. Financial PerTreatmentance
- 10.14.3. Treatment Benchmarking
- 10.14.4. Recent Development